Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc. (ORMP)
Filing Type: Form 8-K (Current Report)
Reporting Date: October 8, 2024 (Earliest event reported: October 7, 2024)
Context: The filing details a complex refinancing and restructuring of Oramed's investment in Scilex Holding Company ("Scilex"). Oramed entered into multiple definitive agreements to refinance a portion of its existing debt (Tranche A Note), acquire new convertible notes and warrants, purchase royalty rights, and establish a joint venture for international licensing.
Key Financial Metrics and Transaction Values
- New Debt Instrument (Tranche B Note): Oramed acquired a senior secured convertible note from Scilex with an initial principal balance of $25,000,000. The aggregate purchase price was $22,500,000 (reflecting a 10% original issue discount).
- Debt Reduction: In exchange for the new Note and related warrants, Oramed reduced the principal outstanding balance of the existing Tranche A Note by $22,500,000.
- Interest Rate: The new Note bears interest at 5.5% per annum, payable quarterly. Upon an event of default, the rate increases to 15.0%.
- Warrants: Oramed received Common Warrants to purchase up to 3,750,000 shares of Scilex Common Stock (part of a total 7.5M issued to all investors) at an exercise price of $1.09 per share.
- Royalty Acquisition: Oramed acquired rights to 4.0% of net sales worldwide for specific lidocaine products (ZTlido, SP-103). The total purchase price for the aggregate 8.0% royalty interest was $5,000,000. Oramed reduced the Tranche A Note principal by $2,500,000 in consideration for its share.
- Recent Cash Payment: Scilex paid Oramed $2,000,000 on September 23, 2024 ($1.7M applied to future amortization, $300k to warrant repurchase).
Material Changes vs. Prior Period
This filing represents a material change in the capital structure of Oramed's investment in Scilex compared to the September 2023 baseline:
- Refinancing: A portion of the original $101.875M Tranche A Note has been refinanced into a new Tranche B Note structure.
- Collateral Priority: A Subordination Agreement was executed. Royalty obligations now hold first-priority liens on specific royalty collateral, while the Tranche A Note and new Tranche B Note hold second-priority liens on that collateral but first-priority on other Scilex assets.
- Payment Extensions: Payment dates for certain Tranche A Note obligations, originally due September 21, 2024, were extended to October 8, 2024 to facilitate the refinancing.
- Joint Venture Formation: A binding term sheet was signed to form "Lido Dev Co," a joint venture to manage Rest of World (ROW) licensing for lidocaine products, with Oramed and institutional investors holding the license.
Guidance, Outlook, Risks, and Unusual Items
- Conversion Terms: The new Notes are convertible into Scilex stock at $1.09/share, subject to a full-ratchet adjustment if Scilex issues stock at a lower price. Conversion is capped at 4.99% beneficial ownership (expandable to 9.99% with notice).
- Redemption Risks: Scilex has the right to redeem the Notes at a 35% premium. Mandatory redemption is triggered by bankruptcy events. Holders have redemption rights upon change of control or asset sales.
- Covenants: The Notes include restrictive covenants limiting Scilex's ability to incur additional debt, pay dividends, or sell assets without consent.
- Waterfall Provisions: An "Agreement Among Holders" establishes a payment waterfall. In the event of a "Waterfall Trigger Event," payments to Tranche A Note holders are prioritized up to a "Maximum First Out Amount" before payments to Tranche B Note holders.
- Regulatory Contingency: The ROW License Term Sheet is subject to obtaining consent from third-party partners (Oishi and Itochu) within 30 days; failure to do so allows the joint venture to negotiate directly.
Investor Verification Checklist
- Verify the exact remaining principal balance of the Tranche A Note after the $25M reduction ($22.5M for the Note swap + $2.5M for the Royalty swap).
- Confirm the status of the third-party consents (Oishi/Itochu) required for the ROW License Term Sheet.
- Review the "Maximum First Out Amount" defined in the Agreement Among Holders to understand the priority of payments in a distress scenario.
- Monitor Scilex's ability to meet the 5.5% interest payments starting January 2, 2025, and whether they will pay in cash or stock.
- Check for any subsequent equity offerings by Scilex that could trigger the full-ratchet adjustment on the conversion price ($1.09) and warrant exercise price.